J T Hays

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Changes in health-related quality of life with smoking cessation treatment
    J Taylor Hays
    Mayo Clinic, Mayo Nicotine Dependence Center, Rochester, MN 55905, USA
    Eur J Public Health 22:224-9. 2012
  2. ncbi Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial
    Richard D Hurt
    Nicotine Dependence Center, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    J Negat Results Biomed 10:1. 2011
  3. ncbi Pharmacologic agents for tobacco dependence treatment: 2011 update
    J Taylor Hays
    Nicotine Dependence Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Atheroscler Rep 14:85-92. 2012
  4. ncbi A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics
    J Taylor Hays
    Department of Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic Nicotine Dependence Center, 200 1st Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 11:859-67. 2009
  5. ncbi Treating tobacco dependence in light of the 2008 US Department of Health and Human Services clinical practice guideline
    J Taylor Hays
    Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:730-5; quiz 735-6. 2009
  6. ncbi Residential treatment compared with outpatient treatment for tobacco use and dependence
    J Taylor Hays
    Nicotine Dependence Center, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:203-9. 2011
  7. ncbi Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence
    J Taylor Hays
    Mayo Clinic Nicotine Dependence Center, 200 1st Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 12:574-81. 2010
  8. ncbi Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study
    J Taylor Hays
    Mayo Clinic, Nicotine Dependence Center, Rochester, Minnesota 55905, USA
    J Subst Abuse Treat 40:102-7. 2011
  9. ncbi Adverse effects and tolerability of medications for the treatment of tobacco use and dependence
    J Taylor Hays
    Mayo Clinic Nicotine Dependence Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Drugs 70:2357-72. 2010
  10. ncbi Efficacy and safety of varenicline for smoking cessation
    J Taylor Hays
    Nicotine Dependence Center, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Med 121:S32-42. 2008

Detail Information

Publications45

  1. ncbi Changes in health-related quality of life with smoking cessation treatment
    J Taylor Hays
    Mayo Clinic, Mayo Nicotine Dependence Center, Rochester, MN 55905, USA
    Eur J Public Health 22:224-9. 2012
    ..We assessed the effects of treatment for tobacco dependence on the health-related QoL in a 52-week randomized controlled trial of varenicline and bupropion sustained release (SR)...
  2. ncbi Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial
    Richard D Hurt
    Nicotine Dependence Center, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    J Negat Results Biomed 10:1. 2011
    ....
  3. ncbi Pharmacologic agents for tobacco dependence treatment: 2011 update
    J Taylor Hays
    Nicotine Dependence Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Atheroscler Rep 14:85-92. 2012
    ..In this review, we provide a current update of pharmacologic agents for tobacco dependence treatment and a discussion of recent controversy regarding adverse effects of some these medications...
  4. ncbi A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics
    J Taylor Hays
    Department of Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic Nicotine Dependence Center, 200 1st Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 11:859-67. 2009
    ..We set out to investigate this issue further by conducting a randomized, double-blind, placebo-controlled trial of bupropion sustained-release (SR) for smoking relapse prevention among abstinent alcoholic smokers...
  5. ncbi Treating tobacco dependence in light of the 2008 US Department of Health and Human Services clinical practice guideline
    J Taylor Hays
    Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:730-5; quiz 735-6. 2009
    ..This article briefly reviews the major updates and recommendations from the new guideline and highlights its practical clinical applications...
  6. ncbi Residential treatment compared with outpatient treatment for tobacco use and dependence
    J Taylor Hays
    Nicotine Dependence Center, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:203-9. 2011
    ..To compare the effectiveness of outpatient vs residential treatment for tobacco dependence in a large referral practice...
  7. ncbi Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence
    J Taylor Hays
    Mayo Clinic Nicotine Dependence Center, 200 1st Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 12:574-81. 2010
    ..In this analysis, we assessed adherence to tobacco dependence treatment, association of adherence with abstinence, and predictors of adherence...
  8. ncbi Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study
    J Taylor Hays
    Mayo Clinic, Nicotine Dependence Center, Rochester, Minnesota 55905, USA
    J Subst Abuse Treat 40:102-7. 2011
    ..No serious adverse events were reported. Varenicline may be a useful aid for treating tobacco dependence among smokers who are in stable recovery from alcohol dependence. Further study of this treatment is warranted...
  9. ncbi Adverse effects and tolerability of medications for the treatment of tobacco use and dependence
    J Taylor Hays
    Mayo Clinic Nicotine Dependence Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Drugs 70:2357-72. 2010
    ..Given these factors, the benefit : risk ratio is strongly in favour of pharmacotherapy for tobacco dependence treatment in virtually all smokers who are motivated to quit...
  10. ncbi Efficacy and safety of varenicline for smoking cessation
    J Taylor Hays
    Nicotine Dependence Center, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Med 121:S32-42. 2008
    ..As the newest agent approved for smoking cessation, the mechanism of action, efficacy, and safety of varenicline...
  11. ncbi Trends in smoking-related diseases. Why smoking cessation is still the best medicine
    J T Hays
    Nicotine Dependence Center, Mayo Clinic, Rochester, MN 55905, USA
    Postgrad Med 104:56-62, 65-6, 71. 1998
    ..But what headway has been made in the reduction of related morbidity and mortality? The authors of this article review the current epidemiologic data on smoking-related diseases and make an indisputable case for smoking cessation...
  12. ncbi Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials
    J T Hays
    Mayo Clinic, Rochester, MN 55905, USA
    Am J Public Health 89:1701-7. 1999
    ..The purpose of this study was to determine the efficacy and safety of the nicotine patch for smoking cessation in an over-the-counter environment. The years of study were 1994 to 1995...
  13. ncbi Residential (inpatient) treatment compared with outpatient treatment for nicotine dependence
    J T Hays
    Nicotine Dependence Center, Division of General Internal Medicine, Mayo Clinic, Rochester, Minn, USA
    Mayo Clin Proc 76:124-33. 2001
    ....
  14. ncbi Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits
    J Taylor Hays
    Mayo Nicotine Dependence Center, Rochester, Minnesota 55905, USA
    CNS Drugs 17:71-83. 2003
    ..Recent postmarketing surveillance reports have raised safety concerns about bupropion, although no causal relationship between bupropion and the reported serious adverse events or death has been established...
  15. ncbi Bupropion sustained release for treatment of tobacco dependence
    J Taylor Hays
    Division of General Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:1020-4; quiz 1024. 2003
    ....
  16. ncbi Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports
    C A Patten
    Nicotine Research Center, Mayo Clinic, Rochester, Minn 55905, USA
    J Clin Psychiatry 60:436-41. 1999
    ..Recent attention has focused on the relationship between depression and smoking cessation. This article describes 5 cases of severe depression that occurred during 2 multicenter trials using bupropion for smoking cessation...
  17. ncbi A community-wide smoking cessation program: Quit and Win 1998 in Olmsted county
    I T Croghan
    Nicotine Research Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Prev Med 33:229-38. 2001
    ..Quit and Win is a community-wide stop smoking contest to help cigarette smokers stop smoking and educate the general public concerning smoking hazards...
  18. ncbi Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial
    J T Hays
    Nicotine Dependence Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Ann Intern Med 135:423-33. 2001
    ..6 kg; P = 0.002) and 104 (4.1 kg vs. 5.4 kg; P = 0.016). CONCLUSIONS: In persons who stopped smoking with 7 weeks of bupropion treatment, sustained-release bupropion for 12 months delayed smoking relapse and resulted in less weight gain...
  19. ncbi Sibutramine for weight gain attenuation during smoking cessation with varenicline: a pilot study
    Amit Sood
    General Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 11:1479-84. 2009
    ..Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. Combining sibutramine and varenicline may facilitate smoking abstinence if weight gain is attenuated...
  20. ncbi Combination pharmacotherapy for stopping smoking: what advantages does it offer?
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Drugs 70:643-50. 2010
    ..Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated...
  21. ncbi Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome
    Richard D Hurt
    Nicotine Research Center, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Addict Behav 27:493-507. 2002
    ..These data should encourage others to perform similar pharmacologic relapse prevention studies with this or other pharmacotherapies...
  22. ncbi Combination treatment with varenicline and nicotine replacement therapy
    Jon O Ebbert
    Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 11:572-6. 2009
    ..A paucity of data exists regarding the safety and effectiveness of combination treatment with varenicline and nicotine replacement therapy (NRT)...
  23. ncbi Treating nondepressed smokers with alcohol dependence in sustained full remission: nicotine patch therapy tailored to baseline serum cotinine
    Richard D Hurt
    Nicotine Dependence Center, Mayo Clinic College of Medicine, 200 First Street South West, Rochester, Minnesota 55905, USA
    J Stud Alcohol 66:506-16. 2005
    ....
  24. ncbi Varenicline and bupropion sustained-release combination therapy for smoking cessation
    Jon O Ebbert
    Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 11:234-9. 2009
    ..Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy...
  25. ncbi Gender differences among smokers receiving interventions for tobacco dependence in a medical setting
    Ivana T Croghan
    Mayo Clinic, Nicotine Dependence Center, 200 First St, SW, Rochester, Minnesota 55905, United States
    Addict Behav 34:61-7. 2009
    ..The purpose of this study was to assess differences between women and men receiving treatment for tobacco dependence through a clinical treatment program...
  26. ncbi The missing link in tobacco control
    Jon O Ebbert
    Nicotine Dependence Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    CMAJ 179:123-4. 2008
  27. ncbi Change in perceived stress, partner support, decisional balance, and self-efficacy following residential nicotine dependence treatment
    Steven C Ames
    Mayo Clinic, Division of Hematology and Oncology, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Addict Dis 27:73-82. 2008
    ..This study provides new information about how residential treatment impacts psychosocial factors considered to be important predictors of tobacco abstinence in outpatient settings...
  28. ncbi Weight concerns among male smokers
    Matthew M Clark
    Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Addict Behav 29:1637-41. 2004
    ..Motivation to quit smoking was found to be significantly lower in those with weight concerns (P < .001). Further investigation is needed to enable the tailoring of interventions for weight-concerned male smokers...
  29. ncbi Nicotine dependence treatment: perceived health status improvement with 1-year continuous smoking abstinence
    Ivana T Croghan
    Nicotine Research Program, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Eur J Public Health 15:251-5. 2005
    ....
  30. ncbi Body image treatment for weight concerned smokers: a pilot study
    Matthew M Clark
    Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Addict Behav 30:1236-40. 2005
    ..At week 12, 7(35%) of the body image participants had 7-day point prevalence smoking abstinence, compared to 5(24%) of the participants in the weight management group (p=0.505)...
  31. ncbi Personality correlates related to tobacco abstinence following treatment
    W Michael Hooten
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Psychiatry Med 35:59-74. 2005
    ..The five-factor model of personality was used to describe the correlates of smoking abstinence...
  32. ncbi Tobacco dependence: why should an oncologist care?
    Yolanda I Garces
    Division of Radiation Oncology, Department of Oncology, Mayo Clinic, 200 First St, SW, Rochester, MN, 55905, USA
    J Clin Oncol 21:1884-6. 2003
  33. ncbi Treating tobacco dependence in a medical setting
    Richard D Hurt
    Nicotine Dependence Center, Mayo Clinic, Rochester, MN 55905, USA
    CA Cancer J Clin 59:314-26. 2009
    ..The effective treatment of tobacco dependence frequently requires tailoring, and often intensifying, interventions (both counseling and pharmacotherapy) to meet the needs of the individual patient...
  34. ncbi Gabapentin for smoking cessation: a preliminary investigation of efficacy
    Amit Sood
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 9:291-8. 2007
    ..Our results suggest that gabapentin may increase smoking abstinence. An adequately powered randomized clinical trial assessing different doses of this drug against a placebo would be the reasonable next step...
  35. ncbi Treating tobacco dependence: review of the best and latest treatment options
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Thorac Oncol 2:249-56. 2007
    ..We review the currently available pharmacologic approaches to the treatment of tobacco dependence...
  36. ncbi Gabapentin for smoking cessation
    Amit Sood
    Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 12:300-4. 2010
    ..We conducted a preliminary proof-of-concept study evaluating gabapentin for the treatment of tobacco dependence...
  37. ncbi Treatment of tobacco dependence
    Michael V Burke
    Nicotine Dependence Center, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:479-83; quiz 483-4. 2008
    ..Because tobacco dependence is characterized by relapses and remissions, clinicians should be ready to engage smokers and reengage relapsed smokers with options for new medication strategies and additional counseling resources...
  38. ncbi The role of smoking in breast cancer development: an analysis of a Mayo Clinic cohort
    Ivana T Croghan
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Breast J 15:489-95. 2009
    ..81, p < 0.001). In this referral practice having a personal history of smoking is predictive of breast cancer diagnosis. Further studies are needed to further explore this relationship...
  39. ncbi Effects of gender on relapse prevention in smokers treated with bupropion SR
    David Gonzales
    Department of Medicine, Oregon Health and Science University, Portland 97201, USA
    Am J Prev Med 22:234-9. 2002
    ..Lower abstinence and higher relapse rates are often reported for women treated with NRT. Gender effects for those treated with non-nicotinic, bupropion-hydrochloride sustained release for relapse prevention have not been studied...
  40. ncbi The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial
    Raymond Niaura
    Brown University, Providence, RI, USA
    Curr Med Res Opin 24:1931-41. 2008
    ..To determine whether self-regulated flexible dosing with varenicline tartrate is safe and effective for smoking cessation...
  41. ncbi Office-based intervention for tobacco dependence
    Susan H Swartz
    Center for Tobacco Independence, Maine Medical Center, 22 Bramhall Street, Portland, ME 04102, USA
    Med Clin North Am 88:1623-41, xii-xiii. 2004
    ..Specific ways to think systematically about smoking cessation and intervene with patients are discussed. Strategies to implement office-based changes to improve tobacco intervention are then presented...
  42. ncbi Characteristics of Air Force personnel who choose pharmacological aids for smoking cessation following an involuntary tobacco ban and tobacco control program
    Robert C Klesges
    Saint Jude Children s Research Hospital, Memphis, TN 38105, USA
    Health Psychol 26:588-97. 2007
    ..The objective of this study was to compare characteristics of smokers who did and did not report use of cessation aids as part of a tobacco control program in a military setting (n = 8994)...
  43. ncbi Effects of biochemically confirmed smoking cessation on white blood cell count
    Gregory A Abel
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Mayo Clin Proc 80:1022-8. 2005
    ..2 +/- 1.5 x 10(9)/L; P < .001). CONCLUSION: Biochemically confirmed tobacco abstinence leads to a rapid and sustained decrease in WBC and ANC, possibly reflecting a decrease In an underlying state of tobacco-induced inflammation...
  44. ncbi Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial
    Douglas E Jorenby
    University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, Wis 53711, USA
    JAMA 296:56-63. 2006
    ..Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine...
  45. ncbi Urinary tobacco alkaloid measurement in patients having thromboangiitis obliterans
    Richard D Hurt
    Mayo Clin Proc 83:1187-8; author reply 1188. 2008